Prestige BioPharma (XKRX:950210) Ending Cash Position : ₩173,318 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Prestige BioPharma Ending Cash Position?

Prestige BioPharma's Ending Cash Position for the quarter that ended in Sep. 2024 was ₩173,318 Mil.

Prestige BioPharma's quarterly Ending Cash Position increased from Mar. 2024 (₩204,809 Mil) to Jun. 2024 (₩210,483 Mil) but then declined from Jun. 2024 (₩210,483 Mil) to Sep. 2024 (₩173,318 Mil).

Prestige BioPharma's annual Ending Cash Position declined from Jun. 2022 (₩249,569 Mil) to Jun. 2023 (₩125,910 Mil) but then increased from Jun. 2023 (₩125,910 Mil) to Jun. 2024 (₩210,483 Mil).

Prestige BioPharma Ending Cash Position Historical Data

The historical data trend for Prestige BioPharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige BioPharma Ending Cash Position Chart

Prestige BioPharma Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Ending Cash Position

45,783.64

461,375.60

249,569.24

125,909.52

210,483.42

Prestige BioPharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Ending Cash Position	Get a 7-Day Free Trial														107,279.22	223,306.45	204,808.60	210,483.42	173,317.95

Prestige BioPharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Prestige BioPharma's Ending Cash Position for the fiscal year that ended in Jun. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	126901.85	+	83581.572
	=	210,483

Prestige BioPharma's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	208439.466	+	-35121.517
	=	173,318

Prestige BioPharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Prestige BioPharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Prestige BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige BioPharma Ltd (XKRX:950210) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Science Park Drive No. 04-13/14, Ascent Tower B, Singapore Science Park, Singapore, SGP, 118222

Website

https://www.prestigebiopharma.com

Prestige BioPharma Ltd is a biopharmaceutical company. The company is focused on the development of biosimilars and new antibody therapeutics. It focuses on oncology and immune disorders, developing new and similar antibody drugs for solid tumor, pancreatic cancer, and arthritis.

Prestige BioPharma Headlines

No Headlines